MAIA Biotechnology (MAIA) Operating Expenses (2021 - 2026)
MAIA Biotechnology (MAIA) posted quarterly Operating Expenses of $6.9 million for Q1 2026, up 28.1% year-over-year from $5.4 million in Q1 2025, and up 60.98% quarter-over-quarter from $4.3 million in Q4 2025.
MAIA Biotechnology (MAIA) Operating Expenses (2021 - 2026) Analysis & Trends
MAIA Biotechnology (MAIA) has reported Operating Expenses for 6 consecutive years, with $6.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses rose 28.1% year-over-year to $6.9 million; the TTM figure through Mar 2026 stood at $25.8 million (up 39.93% YoY), while the FY2025 annual figure was $24.3 million, up 43.12% from the prior year.
- Operating Expenses rose to $6.9 million in Q1 2026 per MAIA's latest filing, from $4.3 million in the prior quarter.
- Across five years, Operating Expenses topped out at $9.4 million in Q3 2025 and bottomed at $3.4 million in Q2 2022.
- Historically, Operating Expenses has averaged $5.0 million across 5 years, with a median of $4.7 million in 2023.
- Annual changes were most pronounced in 2022 — Operating Expenses surged 128.97% — and 2024, when it decreased 21.53%.
- MAIA Biotechnology's Operating Expenses stood at $4.2 million in 2022, then surged by 52.03% to $6.4 million in 2023, then fell by 21.53% to $5.0 million in 2024, then slipped by 13.73% to $4.3 million in 2025, then soared by 60.98% to $6.9 million in 2026.
- Business Quant data shows MAIA's Operating Expenses at $6.9 million in Q1 2026, $4.3 million in Q4 2025, and $9.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 541.02 Mn |
| 10 | MAIA Biotechnology | 84.20 Mn | 56.60 Mn | - | 8.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.32 Mn |
| Mar 31, 2026 | 6.95 Mn |
| Dec 31, 2025 | 4.32 Mn |
| Sep 30, 2025 | 9.36 Mn |
| Jun 30, 2025 | 5.17 Mn |
| Mar 31, 2025 | 5.43 Mn |
| Dec 31, 2024 | 5.00 Mn |
| Sep 30, 2024 | 4.19 Mn |
| Jun 30, 2024 | 3.82 Mn |
| Mar 31, 2024 | 3.95 Mn |
| Dec 31, 2023 | 6.38 Mn |
| Sep 30, 2023 | 4.96 Mn |
| Jun 30, 2023 | 4.66 Mn |
| Mar 31, 2023 | 4.18 Mn |
| Dec 31, 2022 | 4.20 Mn |
| Sep 30, 2022 | 5.10 Mn |
| Jun 30, 2022 | 3.44 Mn |
| Mar 31, 2022 | 3.44 Mn |
| Dec 31, 2021 | 3.00 Mn |
| Sep 30, 2021 | 2.23 Mn |